AU4701799A - Coadministration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions - Google Patents
Coadministration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions Download PDFInfo
- Publication number
- AU4701799A AU4701799A AU47017/99A AU4701799A AU4701799A AU 4701799 A AU4701799 A AU 4701799A AU 47017/99 A AU47017/99 A AU 47017/99A AU 4701799 A AU4701799 A AU 4701799A AU 4701799 A AU4701799 A AU 4701799A
- Authority
- AU
- Australia
- Prior art keywords
- acid
- methyl
- phenyl
- biphenyl
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Furan Compounds (AREA)
- Pyrane Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Indole Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Quinoline Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9363998P | 1998-07-21 | 1998-07-21 | |
| US60093639 | 1998-07-21 | ||
| PCT/US1999/013948 WO2000004892A2 (en) | 1998-07-21 | 1999-06-18 | Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU4701799A true AU4701799A (en) | 2000-02-14 |
Family
ID=22239992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU47017/99A Abandoned AU4701799A (en) | 1998-07-21 | 1999-06-18 | Coadministration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1098662A2 (id) |
| JP (1) | JP2002521328A (id) |
| KR (1) | KR20010083134A (id) |
| CN (1) | CN1310629A (id) |
| AP (1) | AP2001002035A0 (id) |
| AU (1) | AU4701799A (id) |
| BG (1) | BG105162A (id) |
| BR (1) | BR9912296A (id) |
| CA (1) | CA2335062A1 (id) |
| CZ (1) | CZ2001126A3 (id) |
| EA (1) | EA200100153A1 (id) |
| EE (1) | EE200100046A (id) |
| HR (1) | HRP20010055A2 (id) |
| HU (1) | HUP0102880A3 (id) |
| ID (1) | ID30030A (id) |
| IL (1) | IL140982A0 (id) |
| IS (1) | IS5809A (id) |
| NO (1) | NO20010291L (id) |
| OA (1) | OA11584A (id) |
| PL (1) | PL346011A1 (id) |
| SK (1) | SK502001A3 (id) |
| TR (1) | TR200100205T2 (id) |
| WO (1) | WO2000004892A2 (id) |
| YU (1) | YU3501A (id) |
| ZA (1) | ZA200100294B (id) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2382676A1 (en) * | 1999-11-05 | 2001-05-17 | Warner-Lambert Company | Prevention of plaque rupture by acat inhibitors |
| DOP2000000107A (es) | 1999-12-01 | 2002-09-16 | Agouron Pharmaceutical Inc | Compuestos, composiciones y metodos para estimular el crecimiento y alongamiento de las neuronas |
| AU2268401A (en) * | 1999-12-17 | 2001-06-25 | Versicor Inc | Novel succinate compounds, compositions and methods of use and preparation |
| PL362244A1 (en) * | 2000-09-01 | 2004-10-18 | Sankyo Company, Limited | Medicinal compositions |
| GB0100761D0 (en) | 2001-01-11 | 2001-02-21 | Biocompatibles Ltd | Drug delivery from stents |
| CA2479906C (en) * | 2002-04-03 | 2011-02-08 | Topotarget Uk Limited | Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors |
| CA2492035A1 (en) * | 2002-07-11 | 2004-01-15 | Vicuron Pharmaceuticals, Inc. | N-hydroxyamide derivatives possessing antibacterial activity |
| WO2011092284A1 (en) * | 2010-01-29 | 2011-08-04 | Euroscreen S.A. | Novel amino acid derivatives and their use as gpr43 receptor modulators |
| CN104211695B (zh) * | 2013-06-04 | 2017-04-12 | 中国医学科学院医药生物技术研究所 | 一组胺甲酰基苯磺酰类化合物的用途 |
| EP3244883A1 (en) * | 2015-01-15 | 2017-11-22 | Biocant - Associação De Transferência De Tecnologia | Treatment of hutchinson-gilford progeria syndrome and diseases related to vascular ageing |
| CN106831697B (zh) * | 2017-03-15 | 2019-11-05 | 深圳市康道生物有限公司 | 川榛有效提取成分及其在防治动脉粥样硬化中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5366987A (en) * | 1991-08-22 | 1994-11-22 | Warner-Lambert Company | Isoxazolyl-substituted alkyl amide ACAT inhibitors |
| US5491172A (en) * | 1993-05-14 | 1996-02-13 | Warner-Lambert Company | N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents |
| EE9800037A (et) * | 1995-08-04 | 1998-08-17 | Warner-Lambert Company | Sulfaamhappe derivaatide, atsüülsulfoonamiidide või sulfonüülkarbamaatide kasutamine lipoproteiini tasemeid vähendava ravimi valmistamiseks |
| DK0901466T3 (da) * | 1996-05-17 | 2002-02-18 | Warner Lambert Co | Biphenylsulfonamid-matriksmetalloproteinase-inhibitorer |
| BR9711988A (pt) * | 1996-09-04 | 1999-08-24 | Warner Lambert Co | Inibidores de metaloproteinase de matriz e seus empregos terap-uticos |
-
1999
- 1999-06-18 CN CN99808958A patent/CN1310629A/zh active Pending
- 1999-06-18 CZ CZ2001126A patent/CZ2001126A3/cs unknown
- 1999-06-18 SK SK50-2001A patent/SK502001A3/sk unknown
- 1999-06-18 EA EA200100153A patent/EA200100153A1/ru unknown
- 1999-06-18 WO PCT/US1999/013948 patent/WO2000004892A2/en not_active Application Discontinuation
- 1999-06-18 AU AU47017/99A patent/AU4701799A/en not_active Abandoned
- 1999-06-18 IL IL14098299A patent/IL140982A0/xx unknown
- 1999-06-18 EE EEP200100046A patent/EE200100046A/xx unknown
- 1999-06-18 PL PL99346011A patent/PL346011A1/xx unknown
- 1999-06-18 ID IDW20010333A patent/ID30030A/id unknown
- 1999-06-18 OA OA1200100022A patent/OA11584A/en unknown
- 1999-06-18 EP EP99930483A patent/EP1098662A2/en not_active Withdrawn
- 1999-06-18 TR TR2001/00205T patent/TR200100205T2/xx unknown
- 1999-06-18 KR KR1020017000930A patent/KR20010083134A/ko not_active Application Discontinuation
- 1999-06-18 AP APAP/P/2001/002035A patent/AP2001002035A0/en unknown
- 1999-06-18 JP JP2000560885A patent/JP2002521328A/ja active Pending
- 1999-06-18 CA CA002335062A patent/CA2335062A1/en not_active Abandoned
- 1999-06-18 BR BR9912296-0A patent/BR9912296A/pt not_active IP Right Cessation
- 1999-06-18 YU YU3501A patent/YU3501A/sh unknown
- 1999-06-18 HU HU0102880A patent/HUP0102880A3/hu unknown
-
2001
- 2001-01-10 ZA ZA200100294A patent/ZA200100294B/en unknown
- 2001-01-12 IS IS5809A patent/IS5809A/is unknown
- 2001-01-17 BG BG105162A patent/BG105162A/xx unknown
- 2001-01-18 NO NO20010291A patent/NO20010291L/no not_active Application Discontinuation
- 2001-01-19 HR HR20010055A patent/HRP20010055A2/hr not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ID30030A (id) | 2001-11-01 |
| TR200100205T2 (tr) | 2001-05-21 |
| HUP0102880A2 (en) | 2002-06-29 |
| HUP0102880A3 (en) | 2002-11-28 |
| CA2335062A1 (en) | 2000-02-03 |
| IL140982A0 (en) | 2002-02-10 |
| JP2002521328A (ja) | 2002-07-16 |
| NO20010291D0 (no) | 2001-01-18 |
| IS5809A (is) | 2001-01-12 |
| PL346011A1 (en) | 2002-01-14 |
| KR20010083134A (ko) | 2001-08-31 |
| NO20010291L (no) | 2001-01-18 |
| EE200100046A (et) | 2002-06-17 |
| HRP20010055A2 (en) | 2002-04-30 |
| WO2000004892A3 (en) | 2000-05-18 |
| BG105162A (en) | 2001-12-29 |
| WO2000004892A2 (en) | 2000-02-03 |
| AP2001002035A0 (en) | 2001-03-31 |
| CN1310629A (zh) | 2001-08-29 |
| CZ2001126A3 (cs) | 2002-01-16 |
| EP1098662A2 (en) | 2001-05-16 |
| EA200100153A1 (ru) | 2001-08-27 |
| YU3501A (sh) | 2005-06-10 |
| ZA200100294B (en) | 2002-01-10 |
| OA11584A (en) | 2004-07-20 |
| SK502001A3 (en) | 2002-06-04 |
| BR9912296A (pt) | 2001-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU741768B2 (en) | Method for treating and preventing heart failure and ventricular dilatation | |
| AU737117B2 (en) | Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing | |
| AU751701B2 (en) | Ace inhibitor-MMP inhibitor combinations | |
| AU4701799A (en) | Coadministration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions | |
| US20020049237A1 (en) | Statin-MMP inhibitor combinations | |
| US20050020607A1 (en) | Statin-MMP inhibitor combinations | |
| KR20010041916A (ko) | 스타틴-매트릭스 메탈로프로테이나제 저해제 복합제제 | |
| MXPA01000780A (en) | Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions | |
| EP1366765A1 (en) | Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing | |
| MXPA00003736A (en) | Ace inhibitor-mmp inhibitor combinations | |
| MXPA99002254A (en) | Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing | |
| AU2003248291A1 (en) | Statin-matrix metalloproteinase inhibitor combinations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |